Fresenius stock slips 0.73% to EUR 51.49 premarket
Published on 11/06/2026 at 08:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey Premarket Factors
- Fresenius reported third-quarter revenue of EUR 5,803 million, with organic growth of 5 percent.
- Constant-currency Core EPS rose 14 percent, while the company lifted its full-year 2026 outlook.
- The updated outlook calls for Core EPS growth in the upper half of the 10 percent to 15 percent range.
Fresenius stock traded at EUR 51.49 on Lang & Schwarz at 08:15 CET on Friday, November 6, 2026, 0.73 percent below the Xetra close of Thursday, November 5, at EUR 51.87.
Fresenius delivered a strong third quarter and improved its full-year outlook. In its Q3 2026 results release, the healthcare group reported revenue of EUR 5,803 million and organic growth of 5 percent.
Fresenius Raises Earnings Outlook
Group EBIT before special items reached EUR 638 million, up 10 percent in constant currency. The EBIT margin expanded by 50 basis points to 11.0 percent, while Core EPS increased 14 percent in constant currency to EUR 0.72. Fresenius now expects full-year 2026 Core EPS growth in the upper half of its 10 percent to 15 percent range and raised its EBIT margin indication to above 11.5 percent.
Fresenius Kabi generated EUR 391 million in EBIT, with its Growth Vectors contributing more than half of the segment result. Fresenius Helios reported EUR 293 million in EBIT and a margin of 8.6 percent. The figures include operational effects and are presented before special items where stated.
What Investors Watch Next
Investors can use the real-time quote of Fresenius stock to follow the next trading updates as the market assesses the higher earnings outlook and improving margins.
German equities remain the relevant market backdrop for Fresenius, with the DAX providing the main domestic benchmark.
More news and analyses on Fresenius stock provide further company and market coverage.
